MannKind (MNKD) Competitors

$3.36 -0.16 (-4.55%)

Closing price 04:00 PM Eastern

Extended Trading

$3.40 +0.04 (+1.16%)

As of 05:15 PM Eastern

MNKD vs. BCRX, CLDX, INVA, NVAX, and ZBIO

Should you be buying MannKind stock or one of its competitors? The main competitors of MannKind include BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

How does MannKind compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than MannKind. MarketBeat recorded 23 mentions for BioCryst Pharmaceuticals and 19 mentions for MannKind. MannKind's average media sentiment score of 0.16 beat BioCryst Pharmaceuticals' score of 0.04 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

MannKind has a net margin of -6.63% compared to BioCryst Pharmaceuticals' net margin of -51.71%. MannKind's return on equity of -11.21% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
MannKind	-6.63%	-11.21%	-3.92%

BioCryst Pharmaceuticals presently has a consensus price target of $20.70, suggesting a potential upside of 141.26%. MannKind has a consensus price target of $8.84, suggesting a potential upside of 163.21%. Given MannKind's higher probable upside, analysts clearly believe MannKind is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

BioCryst Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$885.72M	2.46	$263.86M	-$1.78	N/A
MannKind	$360.78M	2.88	$5.86M	-$0.07	N/A

Summary

BioCryst Pharmaceuticals beats MannKind on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Celldex Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

MannKind has higher revenue and earnings than Celldex Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,645.23	-$258.76M	-$4.26	N/A
MannKind	$360.78M	2.88	$5.86M	-$0.07	N/A

In the previous week, MannKind had 8 more articles in the media than Celldex Therapeutics. MarketBeat recorded 19 mentions for MannKind and 11 mentions for Celldex Therapeutics. MannKind's average media sentiment score of 0.16 beat Celldex Therapeutics' score of 0.10 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

49.5% of MannKind shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Celldex Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
MannKind	-6.63%	-11.21%	-3.92%

Celldex Therapeutics presently has a consensus price target of $48.00, suggesting a potential upside of 48.70%. MannKind has a consensus price target of $8.84, suggesting a potential upside of 163.21%. Given MannKind's higher probable upside, analysts clearly believe MannKind is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

MannKind beats Celldex Therapeutics on 10 of the 16 factors compared between the two stocks.

How does MannKind compare to Innoviva?

Innoviva (NASDAQ:INVA) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Innoviva has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.06	$271.17M	$6.01	3.75
MannKind	$360.78M	2.88	$5.86M	-$0.07	N/A

In the previous week, MannKind had 10 more articles in the media than Innoviva. MarketBeat recorded 19 mentions for MannKind and 9 mentions for Innoviva. Innoviva's average media sentiment score of 1.17 beat MannKind's score of 0.16 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Innoviva shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
MannKind	-6.63%	-11.21%	-3.92%

Innoviva presently has a consensus price target of $36.20, suggesting a potential upside of 60.75%. MannKind has a consensus price target of $8.84, suggesting a potential upside of 163.21%. Given MannKind's stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Innoviva beats MannKind on 10 of the 16 factors compared between the two stocks.

How does MannKind compare to Novavax?

Novavax (NASDAQ:NVAX) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Novavax has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, MannKind has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Novavax presently has a consensus price target of $12.13, suggesting a potential upside of 27.63%. MannKind has a consensus price target of $8.84, suggesting a potential upside of 163.21%. Given MannKind's stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Novavax has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.39	$440.30M	-$0.58	N/A
MannKind	$360.78M	2.88	$5.86M	-$0.07	N/A

In the previous week, Novavax had 24 more articles in the media than MannKind. MarketBeat recorded 43 mentions for Novavax and 19 mentions for MannKind. Novavax's average media sentiment score of 0.68 beat MannKind's score of 0.16 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	18 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind has a net margin of -6.63% compared to Novavax's net margin of -14.73%. MannKind's return on equity of -11.21% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
MannKind	-6.63%	-11.21%	-3.92%

53.0% of Novavax shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 1.0% of Novavax shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Novavax and MannKind tied by winning 8 of the 16 factors compared between the two stocks.

How does MannKind compare to Zenas BioPharma?

MannKind (NASDAQ:MNKD) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

MannKind has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Zenas BioPharma has a beta of -0.61, suggesting that its stock price is 161% less volatile than the S&P 500.

MannKind presently has a consensus price target of $8.84, suggesting a potential upside of 163.21%. Zenas BioPharma has a consensus price target of $44.14, suggesting a potential upside of 116.07%. Given MannKind's stronger consensus rating and higher possible upside, research analysts plainly believe MannKind is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

MannKind has higher revenue and earnings than Zenas BioPharma. MannKind is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$360.78M	2.88	$5.86M	-$0.07	N/A
Zenas BioPharma	$10M	117.21	-$377.74M	-$7.81	N/A

In the previous week, MannKind had 17 more articles in the media than Zenas BioPharma. MarketBeat recorded 19 mentions for MannKind and 2 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.25 beat MannKind's score of 0.16 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zenas BioPharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Zenas BioPharma	N/A	-85.64%	-61.86%

49.5% of MannKind shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

MannKind beats Zenas BioPharma on 11 of the 16 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNKD vs. The Competition

Export

Metric	MannKind	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.04B	$3.37B	$6.18B	$12.27B
Dividend Yield	N/A	2.24%	2.78%	5.22%
P/E Ratio	-47.99	15.19	20.66	25.70
Price / Sales	2.88	194.53	527.64	64.90
Price / Cash	56.89	56.93	27.81	36.27
Price / Book	-19.76	6.94	9.77	6.74
Net Income	$5.86M	$24.11M	$3.54B	$333.09M
7 Day Performance	N/A	N/A	N/A	0.52%
1 Month Performance	30.74%	4.63%	6.28%	8.98%
1 Year Performance	-26.32%	78.21%	41.81%	42.45%

MannKind Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNKD MannKind	3.6446 of 5 stars	$3.36 -4.5%	$8.84 +163.2%	-22.8%	$1.04B	$360.78M	N/A	400	Earnings Report Analyst Downgrade
BCRX BioCryst Pharmaceuticals	3.6782 of 5 stars	$9.20 +0.1%	$19.64 +113.4%	-13.6%	$2.34B	$874.84M	7.67	530	Earnings Report Analyst Downgrade
CLDX Celldex Therapeutics	2.6095 of 5 stars	$32.77 +1.4%	$46.36 +41.5%	+85.3%	$2.15B	$1.54M	N/A	150	Earnings Report Analyst Forecast
INVA Innoviva	3.9798 of 5 stars	$22.99 -0.5%	$34.80 +51.4%	+23.3%	$1.71B	$411.33M	7.54	100	Positive News Earnings Report Analyst Downgrade
NVAX Novavax	2.0223 of 5 stars	$8.03 -0.1%	$11.88 +47.9%	+68.8%	$1.32B	$1.12B	3.33	1,990	Earnings Report Options Volume Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNKD) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MannKind (MNKD) Competitors

MNKD vs. BCRX, CLDX, INVA, NVAX, and ZBIO

How does MannKind compare to BioCryst Pharmaceuticals?

Summary

How does MannKind compare to Celldex Therapeutics?

Summary

How does MannKind compare to Innoviva?

Summary

How does MannKind compare to Novavax?

Summary

How does MannKind compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MannKind (MNKD) Competitors

MNKD vs. BCRX, CLDX, INVA, NVAX, and ZBIO

How does MannKind compare to BioCryst Pharmaceuticals?

Do institutionals & insiders have more ownership in BCRX or MNKD?

Does the media refer more to BCRX or MNKD?

Which has more risk & volatility, BCRX or MNKD?

Is BCRX or MNKD more profitable?

Do analysts rate BCRX or MNKD?

Which has stronger valuation and earnings, BCRX or MNKD?

Summary

How does MannKind compare to Celldex Therapeutics?

Which has more risk & volatility, CLDX or MNKD?

Which has stronger valuation and earnings, CLDX or MNKD?

Does the media refer more to CLDX or MNKD?

Do institutionals & insiders have more ownership in CLDX or MNKD?

Is CLDX or MNKD more profitable?

Do analysts rate CLDX or MNKD?

Summary

How does MannKind compare to Innoviva?

Which has more volatility and risk, INVA or MNKD?

Which has higher earnings and valuation, INVA or MNKD?

Does the media refer more to INVA or MNKD?

Do insiders and institutionals have more ownership in INVA or MNKD?

Is INVA or MNKD more profitable?

Do analysts rate INVA or MNKD?

Summary

How does MannKind compare to Novavax?

Which has more volatility and risk, NVAX or MNKD?

Do analysts rate NVAX or MNKD?

Which has higher earnings and valuation, NVAX or MNKD?

Does the media refer more to NVAX or MNKD?

Is NVAX or MNKD more profitable?

Do insiders and institutionals have more ownership in NVAX or MNKD?

Summary

How does MannKind compare to Zenas BioPharma?

Which has more risk and volatility, MNKD or ZBIO?

Do analysts rate MNKD or ZBIO?

Which has better earnings & valuation, MNKD or ZBIO?

Does the media prefer MNKD or ZBIO?

Is MNKD or ZBIO more profitable?

Do institutionals and insiders hold more shares of MNKD or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools